495 related articles for article (PubMed ID: 29985080)
21. Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies.
Curtis JR; Weinblatt ME; Shadick NA; Brahe CH; Østergaard M; Hetland ML; Saevarsdottir S; Horton M; Mabey B; Flake DD; Ben-Shachar R; Sasso EH; Huizinga TW
Arthritis Res Ther; 2021 Jan; 23(1):1. PubMed ID: 33397438
[TBL] [Abstract][Full Text] [Related]
22. Brief Report: Estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab.
Fleischmann R; Connolly SE; Maldonado MA; Schiff M
Arthritis Rheumatol; 2016 Sep; 68(9):2083-9. PubMed ID: 27111089
[TBL] [Abstract][Full Text] [Related]
23. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
[TBL] [Abstract][Full Text] [Related]
24. A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study.
Hirata S; Li W; Defranoux N; Cavet G; Bolce R; Yamaoka K; Saito K; Tanaka Y
Mod Rheumatol; 2015 May; 25(3):344-9. PubMed ID: 25295918
[TBL] [Abstract][Full Text] [Related]
25. Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis.
Reiss WG; Devenport JN; Low JM; Wu G; Sasso EH
Rheumatol Int; 2016 Feb; 36(2):295-300. PubMed ID: 26026604
[TBL] [Abstract][Full Text] [Related]
26. A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis.
Ma MHY; Defranoux N; Li W; Sasso EH; Ibrahim F; Scott DL; Cope AP
Arthritis Res Ther; 2020 Jun; 22(1):158. PubMed ID: 32580789
[TBL] [Abstract][Full Text] [Related]
27. Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA).
Hørslev-Petersen K; Hetland ML; Ørnbjerg LM; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
Ann Rheum Dis; 2016 Sep; 75(9):1645-53. PubMed ID: 26489704
[TBL] [Abstract][Full Text] [Related]
28. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints.
Aletaha D; Smolen JS
Arthritis Rheum; 2011 Dec; 63(12):3702-11. PubMed ID: 21953215
[TBL] [Abstract][Full Text] [Related]
29. Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials.
Keystone EC; Ahmad HA; Yazici Y; Bergman MJ
Rheumatology (Oxford); 2020 Aug; 59(8):2090-2098. PubMed ID: 31819995
[TBL] [Abstract][Full Text] [Related]
30. The multi-biomarker disease activity test for assessing response to treatment strategies using methotrexate with or without prednisone in the CAMERA-II trial.
Jurgens MS; Safy-Khan M; de Hair MJH; Bijlsma JWJ; Welsing PMJ; Tekstra J; Lafeber FPJG; Sasso EH; Jacobs JWG;
Arthritis Res Ther; 2020 Sep; 22(1):205. PubMed ID: 32907614
[TBL] [Abstract][Full Text] [Related]
31. Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study.
Bakker MF; Cavet G; Jacobs JW; Bijlsma JW; Haney DJ; Shen Y; Hesterberg LK; Smith DR; Centola M; van Roon JA; Lafeber FP; Welsing PM
Ann Rheum Dis; 2012 Oct; 71(10):1692-7. PubMed ID: 22596166
[TBL] [Abstract][Full Text] [Related]
32. Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial.
Dale J; Stirling A; Zhang R; Purves D; Foley J; Sambrook M; Conaghan PG; van der Heijde D; McConnachie A; McInnes IB; Porter D
Ann Rheum Dis; 2016 Jun; 75(6):1043-50. PubMed ID: 27026689
[TBL] [Abstract][Full Text] [Related]
33. Predictive ability, validity, and responsiveness of the multi-biomarker disease activity score in patients with rheumatoid arthritis initiating methotrexate.
Luedders BA; Johnson TM; Sayles H; Thiele GM; Mikuls TR; O'Dell JR; England BR
Semin Arthritis Rheum; 2020 Oct; 50(5):1058-1063. PubMed ID: 32911284
[TBL] [Abstract][Full Text] [Related]
34. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis.
Emery P; Genovese MC; van Vollenhoven R; Sharp JT; Patra K; Sasso EH
J Rheumatol; 2009 Jul; 36(7):1429-41. PubMed ID: 19369462
[TBL] [Abstract][Full Text] [Related]
35. Plasma MicroRNA Profiles in Patients with Early Rheumatoid Arthritis Responding to Adalimumab plus Methotrexate vs Methotrexate Alone: A Placebo-controlled Clinical Trial.
Sode J; Krintel SB; Carlsen AL; Hetland ML; Johansen JS; Hørslev-Petersen K; Stengaard-Pedersen K; Ellingsen T; Burton M; Junker P; Østergaard M; Heegaard NHH
J Rheumatol; 2018 Jan; 45(1):53-61. PubMed ID: 29142030
[TBL] [Abstract][Full Text] [Related]
36. Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment.
Rech J; Hueber AJ; Finzel S; Englbrecht M; Haschka J; Manger B; Kleyer A; Reiser M; Cobra JF; Figueiredo C; Tony HP; Kleinert S; Wendler J; Schuch F; Ronneberger M; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Lorenz HM; Nuesslein H; Alten R; Henes J; Krueger K; Schett G
Ann Rheum Dis; 2016 Sep; 75(9):1637-44. PubMed ID: 26483255
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice.
Katayama K; Okubo T; Sato T; Ito H; Fukai R; Baba H
Mod Rheumatol; 2015 Jan; 25(1):50-5. PubMed ID: 24983407
[TBL] [Abstract][Full Text] [Related]
38. Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis.
Smolen JS; Pedersen R; Jones H; Mahgoub E; Marshall L
Rheumatology (Oxford); 2020 Jan; 59(1):153-164. PubMed ID: 31257453
[TBL] [Abstract][Full Text] [Related]
39. Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate.
Smolen JS; van Vollenhoven RF; Florentinus S; Chen S; Suboticki JL; Kavanaugh A
Ann Rheum Dis; 2018 Nov; 77(11):1566-1572. PubMed ID: 30076156
[TBL] [Abstract][Full Text] [Related]
40. MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy.
Shiozawa K; Yamane T; Murata M; Yoshihara R; Tsumiyama K; Imura S; Shiozawa S
Arthritis Res Ther; 2016 Feb; 18():55. PubMed ID: 26922083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
